Connect wallet to trade · No wallet? Passkey login available · Free alerts at /subscribe
The prediction market is asking whether a laboratory-confirmed case of Ebola virus disease will occur in the United States by June 30, 2026. Currently trading at 11% YES odds—a relatively low probability—the market reflects trader confidence that US biosecurity, case detection, and containment protocols remain effective. The 11% price suggests traders view this scenario as unlikely but not negligible, particularly given ongoing Ebola transmission in parts of West and Central Africa. Over the past 18 months, traders have maintained the YES side below 15%, indicating sustained belief in US defensive capacity. A case could emerge through healthcare worker exposure during international deployment, rare laboratory incident, or travel-related importation from an active outbreak region. The low current odds imply market participants see the US border and medical screening as sufficient barriers to prevent sustained domestic transmission, even if a single case were to be confirmed.
What factors could move this market?
Ebola virus disease has never sustained human-to-human transmission chains inside the United States, despite multiple cases being diagnosed on US soil since 2014. The 2014–2016 West African outbreak infected over 11,000 people, with four confirmed cases diagnosed in the US—three survived following aggressive supportive care, and one healthcare worker (Thomas Eric Duncan) died before diagnostics were available. That outbreak demonstrated US medical capability: once a case was identified and proper protocols enacted, onward transmission was halted. Today's surveillance systems, biosafety infrastructure, and healthcare training are substantially more mature than in 2014.
The 11% odds reflect a specific worry class: that an international event (an active Ebola outbreak elsewhere, a lab incident, or rare healthcare exposure) could result in importation and diagnosis inside the US. In late 2022–2023, Ebola cases resurfaced in Uganda and the Democratic Republic of Congo with modest case counts. Should another large West African outbreak emerge by June 2026, the probability of a travel-related case entering the US would rise—especially affecting healthcare workers, diplomats, or researchers deployed to affected regions. A second pathway involves laboratory handling: infectious disease research on Ebola is conducted at BSL-4 facilities in the US, and any procedural failure could introduce risk.
Against YES, the market prices in the absence of an active Ebola epidemic outside Africa likely to export cases, the seasonal nature of some Ebola outbreaks driven by bushmeat contact, the aggressive screening and quarantine protocols now deployed at US entry points, and the reality that US hospitals maintain specialized isolation units and training after seeing Ebola twice in the past decade.
The 11% price implies traders expect the risk surface to remain roughly where it is—low, but materially above zero. If an African outbreak suddenly escalated, or if news of healthcare worker infection abroad surfaced, the YES side could spike toward 25–35% on importation fears. Conversely, if the next six months pass without Ebola resurgence in Africa, odds could drift toward 5–8%. US infectious disease preparedness has improved markedly since 2014, and the question is whether traders price in the ~6% baseline probability of a rare importation event versus a more significant outbreak scenario.
What are traders watching for?
World Health Organization confirms absence of active Ebola transmission chains in Africa through Q2 2026.
New Ebola case confirmed in West or Central Africa; increases importation risk perception and market repricing.
US hospital isolation capacity tested or any screening protocol breach; could shift market odds upward.
Healthcare workers or researchers in endemic regions report Ebola exposures; early treatment before travel determines domestic risk.
How does this market resolve?
The market resolves YES if a laboratory-confirmed Ebola virus disease case is diagnosed in the United States on or before June 30, 2026. It resolves NO if no such case is confirmed by that date.
Polymarket Trade is an independent third-party interface to the Polymarket CLOB prediction market exchange on Polygon — not affiliated with Polymarket, Inc. Prediction markets aggregate trader expectations into real-time probability estimates. Every market question resolves YES or NO based on a specific event outcome; traders buy shares of the side they believe will resolve positively. Prices range 0¢ (certain no) to 100¢ (certain yes) and naturally reflect the crowd-implied probability of YES. Polymarket Trade is non-custodial — your funds never leave your wallet. Open the full interactive page linked above to place orders, see order book depth, and execute a trade.
